The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Amicus Therapeutics Inc shares valued at $773,659 were sold by Castelli Jeff on Nov 24 ’25. At $10.16 per share, Castelli Jeff sold 76,158 shares. The insider’s holdings dropped to 439,318 shares worth approximately $4.4 million following the completion of this transaction.
Also, Clark David Michael sold 25,643 shares, netting a total of over 258,933 in proceeds. Following the sale of shares at $10.10 each, the insider now holds 296,975 shares.
Before that, Campbell Bradley L had sold 14,587 shares from its account. In a trade valued at $146,522, the President and CEO traded Amicus Therapeutics Inc shares for $10.04 each. Upon closing the transaction, the insider’s holdings decreased to 14,587 shares, worth approximately $11.4 million.
As published in a research note from Needham on September 18, 2025, Amicus Therapeutics Inc [FOLD] has been rated up from a Hold to a Buy and the price target has been revised to $14. Analysts at Morgan Stanley upgraded the stock from ‘”an Equal-weight”‘ to ‘”an Overweight”‘ outlook in a report released in mid July. As of December 13, 2024, Morgan Stanley has decreased its “an Overweight” rating to a “an Equal-weight” for FOLD. Earlier on September 06, 2024, Jefferies initiated its rating. Their recommendation was “a Buy” for FOLD stock.
Analyzing FOLD Stock Performance
On last trading session, Amicus Therapeutics Inc [NASDAQ: FOLD] rose 1.52% to $10.02. The stock’s lowest price that day was $9.79, but it reached a high of $10.04 in the same session. During the last five days, there has been a surge of approximately 2.98%. Over the course of the year, Amicus Therapeutics Inc shares have jumped approximately 3.73%. Shares of the company reached a 52-week high of $10.57 on 11/24/25 and a 52-week low of $5.51 on 06/25/25.
Support And Resistance Levels for Amicus Therapeutics Inc (FOLD)
According to the 24-hour chart, there is a support level at 9.84, which, if violated, would cause prices to drop to 9.66. In the upper region, resistance lies at 10.15. The next price resistance is at 10.28. RSI (Relative Strength Index) is 71.04 on the 14-day chart, showing overbought technical sentiment.
Is Amicus Therapeutics Inc subject to short interest?
Stocks of Amicus Therapeutics Inc saw a sharp steep in short interest on 2025-11-14 dropping by -0.92 million shares to 18.04 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 18.95 million shares. A decline of -5.08% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.66 of the overall float, the days-to-cover ratio (short ratio) decline to 3.66.
Which companies own the most shares of Amicus Therapeutics Inc (FOLD)?
In terms of Amicus Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 14 in the next 12 months, up nearly 41.84% from the previous closing price of $9.87. Analysts anticipate Amicus Therapeutics Inc stock to reach 14 by 2025, with the lowest price target being 14. In spite of this, 5 analysts ranked Amicus Therapeutics Inc stock as Buy at the end of 2025. On May 30, 2024, Wells Fargo assigned a price target of “an Overweight” to the stock and initiated coverage with a $18.
